Doç. Dr. Esra Turan Erkek

Eğitim

• Doçent  Doçentlik Tarihi: 22/03/2024
• 2011 - 2014 İstanbul Üniversitesi ,İstanbul Tıp Fakültesi İç Hastalıkları A.B.D , Hematoloji  B.D, İstanbul, Türkiye
• 2005-2010 Dr.L.Kırdar Kartal Eğitim ve Araştırma Hastanesi  Dahiliye Kliniği İstanbul, Türkiye
• 1998 - 2004 Uludağ Üniversitesi Tıp Fakültesi Bursa, Türkiye

Deneyim

• 2015-2026 İstanbul Dr.Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye
  
• 2010 Hakkari Devlet Hastanesi ( İç Hastalıkları Hizmet Yükümlülüğü )

Kurs ve Sertifikalar

• XXV. Uygulamalı Akan Hücre Ölçer Eğitimi, Uygulamalı Akan Hücre, İstanbul, Kurs, 17.06.2019 -21.06.2019 (Ulusal)
• J and J GCO Investigator Rave Training Version 3.0, J and J GCO Investigator Rave Training, medidata University, Kurs, 21.09.2012 -21.09.2012 (Uluslararası)
• Hematolojik Onkoloji ve Kemik İliği Transplantasyon Kursu, Hematolojik Onkoloji ve Kemik İliği Transplantasyon, Kıbrıs, Kurs, 07.02.2014 -09.02.2014 (Ulusal)
• 3rd International Conference on Multiple Myeloma Kursu, Multiple Myeloma, Milan, Italy, Kurs, 07.10.2016 -09.10.2016 (Uluslararası)
• THD Akan Hücre Ölçer Eğitimi Miniakademi 2026
• THD İTP Bite-   Class Eğitimi 2025

Uzmanlık Tezi

Evre 1 ve Evre 2 Kronik Böbrek Yetersizliğinin Dipper ve Non Dipper Kan Basıncı Paterni Gelişimine Etkisi (2010) Tez Danışmanı Prof Dr Zerrin Bicik Bahçebaşı

Yan Dal Uzmanlık Tezi : Paroksismal Noktürnal Hemoglobinüri ve Aplastik Anemi Olgularında Doaşan Endotel Hücreleri ve Tromboza Etkisi( 2014) Tez Danışmanı ( Prof Dr Mustafa N Yenerel)

Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

1.1.1          Sahin F, Saydam G, Cömert M, Uz B, Yavuz AS, Turan E, Yönal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gürkan E, Paydaş S, Kahraman S, Demirkan F, Kırkızlar O, Akpınar S, Pamuk GE, Demir M, Ozbaş HM10, Sönmez M10, Gültürk M, Salihoğlu A, Eşkazan AE, Ar C, HaydaroğluŞahin H, Ongören S, Başlar Z, Aydın Y, Yenerel MN, Tüzüner N, Ferhanoğlu B, Haznedaroglu IC, Ilhan O, Soysal T.Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.Turk J Haematol. 2013 Dec;30(4):351-8. doi: 10.4274/tjh.2013.0151. Epub 2013 Dec 5

1.1.2          TuranErkekE,Kalayoglu-BesısıkS.An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum .Turk J Haematol. 2016 Mar 5;33(1):81-2. doi: 10.4274/tjh.2015.0268

1.1.3          Turan Erkek E, Karaali CN, Yılmaz G, Gültürk E. Bleomycin-Induced Flagellate Dermatitis. Turk J Haematol. 2019 May 3;36(2):138-140. doi: 10.4274/tjh.galenos.2019.2018.0317. Epub 2019 Jan 2. PMID: 30600679; PMCID: PMC6516091.

1.1.4          Beyhan Sagmen S, Comert S, Turan Erkek E, Küçüköz Uzun A, Doğan C, Yılmaz G, Kıral N, Fidan A, Yılmaz Haksal Ç, Torun Parmaksız E. Can We Predict Bleomycin Toxicity with PET-CT? Acta Haematol. 2019;142(3):171-175. doi: 10.1159/000502374. Epub 2019 Aug 27. PMID: 31454795.

1.1.5          Dogan EE, Turan Erkek E, Elverdi T, Celik Kamaci S, Ciftci U, Demirel N, Aydin D, Eren R. Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul. Indian J Hematol Blood Transfus. 2022 Apr;38(2):327-332. doi: 10.1007/s12288-021-01462-5. Epub 2021 Jul 5. PMID: 35496971; PMCID: PMC9001770..

1.1.6          Erkek ET, Nazligul E, Nalcaci M, Yenerel MN. Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia. Indian J Hematol Blood Transfus. 2022 Apr;38(2):319-326. doi: 10.1007/s12288-021-01445-6. Epub 2021 May 26. PMID: 35496969; PMCID: PMC9001756.

1.1.7          Uğur MC, Namdaroğlu S, Doğan EE, Turan Erkek E, Nizam N, Eren R, Bilgir O. Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura. Turk J Haematol. 2021 Aug 25;38(3):181-187. doi: 10.4274/tjh.galenos.2021.2021.0216. Epub 2021 Jun 24. PMID: 34162173; PMCID: PMC8386313.

1.1.8           Turan Erkek E, Aslan E. Additional malignancies shorten overall survival in chronic lymphocytic leukemia irrespective of chromosomal aberrations: A retrospective cohort study. Medicine (Baltimore). 2023 Feb 10;102(6):e32906. doi: 10.1097/MD.0000000000032906. PMID: 36820600; PMCID: PMC9907968.

1.1.9          Turan Erkek E, Tahtalı T. Co-occurrence of multiple thrombophilic factors with a popliteal artery embolism history: an extraordinary myelofibrosis case. Kuwait Medical Journal, September 2022 Vol 54 No:3 , 405-408

1.1.10       Erkek, ET; Isik, AC1; Ipek, Y; Kul, AN. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio. Nigerian Journal of Clinical Practice 26(6):p 802-809, June 2023. | DOI: 10.4103/njcp.njcp_755_22

1.1.11       Tuna, MK; Erkek, ET. Is Immune Thrombocytopenia and its Treatment Associated with Sarcopenia?. Nigerian Journal of Clinical Practice 27(2):p 180-187, February 2024. | DOI: 10.4103/njcp.njcp_41_23

1.1.12       Doğan EE, Keklik Karadağ F, Aydin D, DemirelN, Sağlam S, Davulcu EA,Turan Erkek E, Eren R, Akad Soyer N; Şahin F, Saydam G. "The assessment of health-related quality of life in patients with polycythemia vera." Medicine 103.30 (2024): e38814. DOI: 10.1097/MD.0000000000038814

Uluslararası diğer hakemli dergilerde yayınlanan makaleler 

1.2.1           Ogret Y, Erkek E, OsmanbasogluE,Yonal İ, SavranOguz F, Nalcacı M, Yavuz AS, KalayogluBesısık S. Restoring of donor chimerism by thyrosine kinase inhibitor treatment in relapsed chronic myeloid leukemia after allogeneic transplantation . Tissue Antigens Volume 84, Number 1 July 2014

1.2.2           Turan Erkek E, Demir N, Ozkan G, Yavuz AS. Testicular and CutaneousRelapse in Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Chemotherapy. Eurasian Journal of Medicine and Oncology. Volume 1, Issue 1,2017.doi: 10.14744/ejmo.2017.87597 Pages 53-54

1.2.3           Cetinkaya Esen H, Gulturk E, Turan Erkek E, Ustaoglu M. Etiological Investigation Of Patients Visiting A Hematology Polyclinic For Anemia. EJMI. 2019; 3(3): 173-181

1.2.4           Turkmen Bekmez E, Volkan O, Demir N, Turan Erkek E, Ataman Tasan D, Aliustaoglu M. Relationship Between Rheumatoid Arthritis Activation Criteria and Serum Hepcidin Levels. EJMI. 2019; 3(4): 275-279

1.2.5           Turan Erkek E, Akın S, Ozgur Y, Aydın Z, Bicik Z. Comparison of DipperandNon-DipperHypertensionPatternsAccordingtoChronicKidneyDiseaseStage. Journal Of NephrologyAdvancesVol No:1 İssue2: 15-23 September 2019DOI: 10.14302/issn.2574-4488.jna-19-3008

1.2.6           Alp Posteki E, Turan Erkek E,Posteki G, Erkek A, Aliustaoglu M. The Correlation Between Systemic Inflammatory ResponseandSurvival in Patients with Metachronous and Synchronous Liver Metastatic Colorectal Cancer. Eurasian Journal of Medical İnvestigation.Volume:4 İssue:1-2020;4(1):17–23/ DOI:10.14744/ejmi.2019.18112

1.2.7           Doğan EE, Demirel N, Turan Erkek E, Aydın D, Mansuroğlu İ, Cömert Özkan M, Eren R. Treatment Outcomes in Hairy Cell Leukemia: Data of Patients in a Tertiary Referral Hospital in Turkey for Over 20 Years. Med J Bakirkoy 2021;17:320-326. 10.4274/BMJ.galenos.2021.85047

1.2.8           Dogan, E. E., Karadag, F. K., Aydin, D., Demirel, N., Davulcu, E. A., Erkek, E. T., ... & SAYDAM, G. (2021). The Effect of Serum Lactate Dehydrogenase (LDH) Level on the Response to Erythropoiesis Stimulating Agents in Patients with Low and Intermediate Risk Myelodysplastic Syndrome. Journal of Haematology and Stem Cell Research, 1(2), 89-97.

1.2.9           Turan Erkek E, Demir N , Erdem S, Ozkan G, Arslan O, Kalayoglu Besısık S.Erdheim–Chester disease: a single center experience. Hematology Transfusion and Cell Therapy 42:59-60.October 2020 DOI: 10.1016/j.htct.2020.09.107. LicenseCC BY-NC-ND 4.0

1.2.10        Evman, Melis Demirag, and Esra Turan Erkek. "Does Chronic Immune Thrombocytopenia Lead to Hearing Loss?." Medical Science and Discovery 9.10 (2022): 577-580.

1.2.11        Ipek Y, Erkek ET. Hematological Malignancies in the Coronavirus Disease-2019 Era: Evaluation of Patient Outcomes and the Reasons for Vaccination Hesitation. jms [Internet]. 2022Nov.24 [cited 2023Jan.9];25(4